Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is associated with decreased expression of AP-1 and NF-κB

International Journal of Molecular Medicine

Volumn 28, Issue 5, 2011, Pages 847-853

  Parra, Eduardo ^a   Ferreira, Jorge ^b   Saenz, Leonardo ^b  

^a UNIVERSIDAD DE TARAPACÁ   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Activator protein 1; Cellular inhibitor of apoptosis 2; Early growth response gene; Nuclear factor B; p21; Prostate carcinoma; Short interfering RNA

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P50; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CELL VIABILITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; ONCOGENE C FOS; ONCOGENE C JUN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL LINE, TUMOR; EARLY GROWTH RESPONSE PROTEIN 1; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 80053101738     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.745     Document Type: Article

References (44)

1. Eichelberger L, O Koch M, Eble J, Ulbright T, Juliar B and Cheng L: Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 18: 886-890, 2005. (Pubitemid 41059947)
2. Virolle T, Krones-Herzig A, Baron V, Gregorio GG, Adamson ED and Mercola D: Egr-1 promotes growth and survival of prostate cancer cells: identification of novel Egr-1 target genes. J Biol Chem 278: 11802-11810, 2003. (Pubitemid 36800149)
3. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG and Tindall DJ: Expression of early growth response genes in human prostate cancer. Cancer Res 58: 2461-2472, 1998.
4. Scharnhorst V, Menke AL and Attema J: EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 19: 791-800, 2000. (Pubitemid 30107710)
5. Pignatelli M, Luna-Medina R, Perez-Rendon A, Santos A and Perez-Castillo A: The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells. Biochem J 373: 739-746, 2003. (Pubitemid 36981083)
6. H ouston P, Campbell CJ, Svaren J, Milbrandt J and Braddock M: The transcriptional corepressor NAB2 blocks Egr-1-mediated growth factor activation and angiogenesis. Biochem Biophys Res Commun 283: 480-486, 2001.
7. Collins S, Lutz MA, Zank PA, Anders R, Kersh G, and Powell JD: Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2 and Egr-3. Eur J Immunol 38: 528-536, 2008.
8. Amorino G, Hamilton V, Valerie K, Dent P, Lamering G and Schmidt-Ullrich R: Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 13: 2233-2244, 2002. (Pubitemid 34831329)
9. Adamson ED and Mercola D: Egr-1 transcription factor, multiple roles in prostate tumor cell growth and survival. Tumour Biol 23: 93-102, 2002. (Pubitemid 34639111)
10. Banks MF, Gerasimovskaya EV, Tucker D, Frid MG, Carpenter TC and Stenmark KR: Egr-1 antisense oligonucleotide inhibit hypoxia-induced proliferation of pulmonary artery adventitial fibroblast. J Appl Physiol 98: 732-738, 2004. (Pubitemid 40129989)
11. White E: Life death, and the pursuit of apoptosis. Genes Dev 10: 1-15, 1996.
12. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP and Rangnekar VM: Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem 272: 20131-20138, 1997. (Pubitemid 27340120)
13. Liu C, Rangnekar VM, Adamson E and Mercola D: Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 5: 3-28, 1998. (Pubitemid 128639987)
14. H an SS, Keum YS, Seo HJ and Surh YJ: Curcumin suppresses activation of NF-κB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol 35: 337-342, 2002.
15. Dhar A, Young MR and Colburn NH: The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 234-235: 185-193, 2002. (Pubitemid 34777856)
16. Suzukawa K, Weber TJ and Colburn NH: AP-1, NF-kappa-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model. Environ Health Perspect 110: 865-870, 2002.
17. Quantin B and Breathnach R: Epidermal growth factor stimulates transcription of the c-Jun protooncogene in rat fibroblasts. Nature 334: 538-539, 1988.
18. Karin M: Signal transduction and gene control. Curr Opin Cell Biol 3: 467-473, 1991.
19. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270: 16483-16486, 1995.
20. Baeuerle PA and Henkel T: Function and activation of NF- &καππα;B in the immune system. Annu Rev Immunol 12: 141-179, 1994.
21. Blackwell TS and Christman JW: The role of nuclear factorkappa B in cytokine gene regulation. Cell Mol Biol 17: 3-9, 1997. (Pubitemid 127500814)
22. Adcock IM: Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 52: 178-186, 1997.
23. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998. (Pubitemid 28538613)
24. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL and Lenardo MJ: A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354, 2000. (Pubitemid 30448156)
25. Gartel AL: Is p21 an oncogene? Mol Cancer Ther 5: 1385-1388, 2006.
26. Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414, 2009.
27. James MA, Lee JH and Klingelhutz AJ: Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol 80: 5301-5307, 2006.
28. Faherty CS and Maurelli AT: Staying alive: bacterial inhibition of apoptosis during infection. Trends Microbiol 16: 173-180, 2008.
29. Mica L, Härter L, Trentz O and Keel M: Endotoxin reduces CD95- induced neutrophil apoptosis by cIAP-2-mediated caspase-3 degradation. J Am Coll Surg 199: 595-602, 2004. (Pubitemid 39420212)
30. Parra E, Ortega A and Saenz L: Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3. Oncol Rep 22: 1513-1518, 2009.
31. Parra E and Ferreira J: Knockdown of the c-Jun-N-terminal kinase expression by siRNA inhibits MCF-7 breast carcinoma cell lines growth. Oncol Rep 24: 1339-1345, 2010.
32. Parra E and Ferreira J: The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines. Oncol Rep 22: 1159-1165, 2010.
33. Inostroza J, Saenz L, Calaf G, Cabello G and Parra E: Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity. Biol Res 38: 163-178, 2005. (Pubitemid 41535617)
34. Parra E, McGuire K, Hedlund G and Dohlsten M: Overexpression of RelA and c-Jun substitutes for B7-1 costimulation by targeting the CD28RE within the IL-2 promoter. J Immunol 160: 5374-5381, 1998. (Pubitemid 28267826)
35. Parra E, Varga M, Hedlund G, Kalland T and Dohlsten M: Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT binding. Mol Cell Biol 17: 1314-1322, 1997.
36. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J and Korneluk RG: Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 105: 11778-11783, 2008.
37. Zheng C, Kabaleeswaran V, Wang Y, Cheng G and Wu H: Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell 38: 101-113, 2010.
38. Parra E, Ferreira J and Ortega A: Overexpression of EGR-1 modulates the activity of NF-κB and AP-1 in prostate carcinoma PC-3 and LNCaP cell lines. Int J Oncol 39: 345-352, 2011.
39. Eid M, Kumar M, Bostwick D and Tindall D: Expression of early growth response genes in human prostate cancer. Cancer Res 58: 2461-2468, 1998. (Pubitemid 28252710)
40. Baron V, Gregorio G, Krones-Herzig A, Virolle T, Calogero A, Urcis R and Mercola D: Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 22: 4194-4204, 2003. (Pubitemid 36876240)
41. Adamson E and Mercola D: Egr-1 transcription factor: multiple roles in prostate tumor cell growth and survival. Tumour Biol 23: 93-102, 2002. (Pubitemid 34639111)
42. Doraia T and Aggarwal B: Role of chemopreventive agents in cancer therapy. Cancer Lett 215: 129-140, 2004.
43. Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP Jr and Ho NW: Biologic Activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J Altern Complement Med 9: 491-497, 2003. (Pubitemid 37051539)
44. Rincón, M and Flavell RA: AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J 13:4370-4381, 1994. (Pubitemid 24295209)